Search Results for “EC” – Page 387 – media

VR Can Alleviate Brain Tumor Patients’ Anxiety During Treatment, Study Finds

AppliedVR teamed up with the National Cancer Institute to study the feasibility of VR to alleviate anxiety in brain tumor patients undergoing imaging scans. The research partners recently announced interim analysis results from their clinical study — they said that not only would VR intervention be a feasible option to reduce patients’ anxiety, but that patients would report high satisfaction levels as well. Patients diagnosed with brain tumors experience notably higher levels of significant distress compared to other solid tumor patients. This heightened distress can be attributed to the disease’s demanding clinical trajectory, as well as its high symptom burden. On top of these challenges, patients with brain tumors face the additional hardship of undergoing frequent neuroimaging assessments to monitor the progress of their disease, leading to what is often referred to as “scanxiety.” This term refers to the anxiety and stress resulting from the anticipation of these medical scans and their potential ...
- Source: drugdu
- 81
- July 25, 2023
Bariatric Surgery Slowdown Nips Intuitive Surgical’s Q2 Procedure Growth

Intuitive Surgical posted strong robotic volume growth in the second quarter and raised its full-year procedure outlook but said patient interest in new weight-loss drugs is curbing demand for bariatric surgeries. The Sunnyvale, California-based robotic surgery leader, on its earnings call Thursday, forecast overall procedure growth in a range of 20% to 22% for the full year, up from the company’s prior forecast of 18% to 21%. In the second quarter, global procedures using Intuitive’s da Vinci surgical robots rose 22%, boosted by demand for general surgery, including hernia repair, colorectal and thoracic procedures, and gynecology and urology procedures. Surgical volumes benefited from higher hospital admissions, especially in the U.S., as healthcare providers catch up with patients whose treatments were delayed during the pandemic, company executives said. “Lower utilization happened over a several-year period, and it will probably take many quarters for it to fully ...
- Source: drugdu
- 142
- July 24, 2023
Pfizer and Flagship Pioneering Sign Drug Discovery Partnership Worth up to $7bn

Pfizer has signed a deal with Flagship Pioneering worth up to $7bn to develop new drug candidates using the venture firm’s large portfolio of biopharma companies. Under the terms of the agreement, Pfizer and Flagship will each invest $50m upfront to develop a new pipeline of up to ten programmes for areas including internal medicine, oncology, infectious diseases, and immunology. The new partners outlined in a statement that the collaboration will focus on addressing unmet needs within Pfizer’s core therapeutic areas, including “broad patient populations and diseases with high potential to benefit from a diverse range of technology platforms and modalities”. Flagship’s drug discovery initiative, Pioneering Medicines, working in collaboration with Pfizer’s research and development leadership, will lead the exploration process. Paul Biondi, president, Pioneering Medicines, and executive partner, Flagship Pioneering, said: “This new partnership brings together the best of our organisations to maximise discovery and ...
- Source: drugdu
- 109
- July 24, 2023
Kenvue Shares Fall Even as J&J Spinoff Beats Estimates in First Quarterly Earnings Since IPO

Kenvue shares fell on Thursday even though the consumer health company beat second-quarter revenue and earnings expectations in the its first quarterly report since it spun out from Johnson & Johnson two months ago. The company, formerly J&J’s consumer health division, also issued an upbeat sales outlook for 2023. Kenvue CEO Thibaut Mongon said during an earnings call that the consumer landscape “continues to be uncertain” and the company expects “market volatility will continue.” But he noted that consumers are still willing to buy “trusted” and “efficacious” health products. Kenvue’s beat was driven by resilient demand for its wealth of widely known brands such as Band-Aid, Tylenol, Listerine, Neutrogena and Aveeno. “This quarter was yet another proof point, showcasing the power of our portfolio,” Mongon said during the call. J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction ...
- Source: drugdu
- 115
- July 24, 2023
Sandoz Invests $90m to Build a Biosimilar Centre in Slovenia

Sandoz has invested $90m to build a biopharma development centre in Ljubljana, Slovenia by 2026. The site will serve to develop biosimilar products and is expected to create 200 new jobs. This follows Novartis’ financial report stating $2.4bn in net sales for Sandoz biosimilars in Q2 2023, along with the proposed 100% separation of Sandoz from Novartis to form an independent company by the end of this year. The fully independent Sandoz will be headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange and American Depositary Receipt (ADR) programme in the US, as per a 1 June press release. To that end, the development centre is the company’s second major investment in Slovenia. In March, the Novartis spin-off announced plans to construct a biologics production plant in Lendava, Slovenia, to support the increasing product demand. According to a press release, Sandoz chief ...
- Source: drugdu
- 108
- July 24, 2023
Novartis acquires DTx Pharma in deal worth up to $1bn

Novartis has announced its acquisition of DTx Pharma, a preclinical stage biotech focused on developing siRNA therapies for neuroscience indications, in a deal worth up to $1bn. The transaction gives Novartis access to DTx’s fatty acid ligand-conjugated oligonucleotide (FALCON) platform as well as its lead preclinical therapy for Charcot-Marie-Tooth disease type 1A (CMT1A). Approximately 150,000 people in the US and Europe are affected by CMT1A, a slow-progressing and degenerative disease of the peripheral nervous system. There are currently no approved treatments to address the underlying genetic cause of the condition: the over-expression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally. DTx-1252, which was recently granted Orphan Drug Designation by the US Food and Drug Administration, decreases the expression of this protein. “The FALCON platform facilitates this targeted approach by conjugating siRNAs to naturally occurring fatty acids ...
- Source: drugdu
- 136
- July 22, 2023
Sandoz doubles down on biosimilars with $90M Slovenia site where it plans to hire 200

Sandoz is doubling down on its commitment to Slovenia in its globe-trotting biosimilar growth quest.The Novartis generics unit is plugging $90 million into a new biosimilar technical development center in Ljubljana, Slovenia, where the company aims to hire 200 new staffers. The new site, which Sandoz says will become “key” to its biosimilar development, will feature end-to-end drug substance and drug product development, the company said in a press release Thursday. This isn’t Sandoz’s first foray into the Balkan country. The announcement follows the company’s recent plan to invest a whopping $400 million in a new manufacturing plant there in Lendava. What’s more, Sandoz has already set up prior complex generic development capabilities in Ljubljana. Nearby, the company is also expanding its biosimilar development firepower in Holzkirchen, Germany. The latest move comes shortly after Sandoz unveiled its Act4Biosimilars action plan in June, under which it’s angling to triple global biosim ...
- Source: drugdu
- 110
- July 22, 2023
Bodybuilding supplement may help stave off progression of Alzheimer’s

by Rush University Medical Center Graphical abstract. Credit: Cell Reports (2023). DOI: 10.1016/j.celrep.2023.112717 RUSH researchers recently discovered that a muscle-building supplement called beta-hydroxy beta-methylbutyrate, also called HMB, may help protect memory, reduce plaques and ultimately help prevent the progression of Alzheimer’s disease. Results from the study were published in Cell Reports. HMB is not a prescription drug or a steroid, but an over-the-counter supplement that is available in sports and fitness stores. Bodybuilders regularly use HMB to increase exercise-induced gains in muscle size and strength while improving exercise performance. HMB is considered safe even after long-term use, with no known side effects. “This may be one of the safest and the easiest approaches to halt disease progression and protect memory in Alzheimer’s disease patients,” said Kalipada Pahan, Ph.D., the Floyd A. Davis, MD, Professor of Neurology and professor of neurological sciences, biochemistry and pharmacology at RUSH Medical College. Reduces plaques ...
- Source: drugdu
- 111
- July 22, 2023
Sanofi Puts Up $125M to Partner on Oral Drug That Could Be Dupixent’s Successor

Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent. By FRANK VINLUAN Photo: Nathan Laine/Bloomberg, via Getty Images Sanofi is a dominating presence in inflammation and immunology with Dupixent, a blockbuster drug whose sales continue to grow in multiple approved indications. That product is an antibody administered by injection, so several companies are vying to compete by developing oral alternatives. Now Sanofi is joining them. The Paris-based pharmaceutical giant has struck up a partnership with Recludix Pharma. The deal focuses on the biotech’s preclinical oral small molecules, which have potential applications in a range of immunological and inflammatory diseases. Sanofi has committed to $125 million in near-term payments to Recludix to begin the alliance. San ...
- Source: drugdu
- 106
- July 22, 2023
Shifting tides for weight loss drugs

By Katie Palmer and Lizzy Lawrence As GLP-1 drugs grow in popularity, businesses are adapting to handle the influx of interest. At Noom, which grew up as a behavior-based coaching tool for weight loss, that has meant the launch of a new service to prescribe weight loss medications — and on Wednesday, a new CEO to head up the company. Geoff Cook, who previously led online dating company the Meet Group, will replace founder Saeju Jeong, who will now be executive chairman. Meanwhile, TikTok is cracking down on some users who post frequently about the weight loss drugs. The social media platform has played a large role in the demand for GLP-1s, but earlier this month, TikTok banned dozens of accounts, many of which make money via partnerships with weight loss-focused telehealth companies. “My hunch is TikTok may be worried about this potential avalanche of concern coming from both irresponsible ...
- Source: drugdu
- 102
- July 22, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.